drugset / Trial / NCT04894227

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

NCT04894227

Phase 4 Completed 1080 enrolled Sinovac Research and Development Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine (CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to evaluate the lot-to-lot consistency, immunogenicity and safety of CoronaVac in healthy adults aged 26-45 years.

Timeline

Start
2021-05-11
Primary completion
2021-05-11
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CoronaVac Vaccine 600 unknown

Indications